Mesoblast wins Japanese approval for stem cell product – The Australian Financial Review
The Australian Financial Review |
Mesoblast wins Japanese approval for stem cell product
The Australian Financial Review TEMCELL is indicated as a treatment for children/adults with acute Graft Versus Host Disease (aGvHD) a severe complication arising from a hemopoietic stem cell transplant—HSCT (a treatment for certain cancers which utilises stem cells derived from … |
